Accrued expenses and other current liabilities consisted of (in thousands):


	June 30, 2025		December 31, 2024
Accrued contracted research and development costs	$	5,235	$	3,912
Accrued compensation		2,259	$	5,017
Accrued general and administrative costs		1,295		1,134
Lease liability		90		116
Total accrued expenses and other current liabilities	$	8,879	$	10,179

As of June 30, 2025, Accrued contracted research and development costs are primarily comprised of costs associated with MOLBREEVI for the treatment of autoimmune PAP, including expenses resulting from obligations under agreements with CROs, CMOs, and other outside service providers that provide services in connection with the Company's research and development activities.

As of June 30, 2025, Accrued compensation includes amounts to be paid to employees for salary, bonuses, vacation and non-equity performance-based compensation. At the end of any period, the amounts accrued for such compensation may vary due to many factors including, but not limited to, timing of payments to employees and vacation usage.